FDA Weighs Peptide Reclassification as Telehealth Giants Prepare for Boom
The Food and Drug Administration (FDA) is meeting on July 23 and 24 to decide whether to reclassify a group of peptides, potentially allowing compounding pharmacies to legally produce custom mixes of these substances. The move would reverse a 2023 Biden administration decision that barred certain peptides from being compounded. Industry insiders widely expect approval despite opposition from career scientists at the agency.
Telehealth companies, including Hims & Hers Health and Mochi Health, are already positioning themselves for what they anticipate will be a lucrative new market. Hims & Hers purchased a peptide manufacturing facility in February 2025 and is developing clinical protocols, while Mochi Health CEO Myra Ahmad told WIRED that pharmacies are finalizing safety testing and pricing.
The hearing comes after Health and Human Services Secretary Robert F. Kennedy Jr. told podcast host Joe Rogan earlier this year that the government intended to loosen restrictions on peptide production. Kennedy, a prominent advocate for alternative health treatments, has personally promoted peptides like BPC-157 and TB-500, often referred to as the "Wolverine stack" for their purported healing and recovery benefits.
What Are Peptides and Why Do They Matter?
Peptides are short chains of amino acids that act as signaling molecules in the body, influencing processes like muscle growth, tissue repair, inflammation, and metabolism. Once a niche interest among bodybuilders and biohackers, they have entered the mainstream due to celebrity endorsements and aggressive marketing by online influencers.
The Compounding Loophole
Compounding pharmacies create customized medications by mixing ingredients in ways that mass manufacturers cannot. The 2023 ban prevented them from compounding certain peptides, citing safety concerns. If the FDA reclassifies these peptides, compounding pharmacies could legally produce them in large volumes, effectively creating a gray market that bypasses formal drug approval processes.
Key Peptides Under Review
- BPC-157 (Body Protection Compound-157): Purported to accelerate healing of tendons, ligaments, and digestive tract. It is one-half of the "Wolverine stack" and has enthusiastic followings among athletes and injury recovery communities.
- TB-500 (Thymosin Beta-4): Often combined with BPC-157 in the "Wolverine stack," it is claimed to promote cell migration and tissue repair.
- Other GLP-1-related peptides: Companies like Mochi Health, originally focused on GLP-1 medications such as semaglutide, are now eyeing broader peptide portfolios.
The Stakes: Safety, Regulation, and a New Cash Cow
Proponents argue that loosening restrictions will improve access to potentially beneficial therapies for patients who do not respond to conventional treatments. Opponents, including many FDA scientists, warn that unregulated peptide compounding could lead to contamination, dosing errors, and unknown long-term effects.
The GLP-1 Precedent
The GLP-1 drug boom — driven by obesity and diabetes medications like Ozempic and Wegovy — has already demonstrated that injectable medications can be highly profitable for telehealth platforms. The same companies now see peptides as the next frontier. According to Cole Thomas, director of sales at pharmacy marketing platform RxConnexion, compounding pharmacy clients are already testing likely popular peptides.
Telehealth Companies in a Race to Market
- Hims & Hers Health: Purchased a peptide manufacturing facility in February 2025, signaling a major strategic pivot.
- Mochi Health: Originally a GLP-1 telehealth company, now preparing peptide offerings with pharmacies that have completed safety testing.
- Olympia Pharmaceuticals: President Joshua Fritzler says the company has spent heavily on formula development in anticipation of FDA approval.
This race recalls the early days of the GLP-1 telehealth gold rush, where companies rapidly scaled up operations to meet demand, sometimes at the expense of rigorous safety oversight.
Political Influence and Scientific Skepticism
The FDA's internal divisions are stark. Career scientists have recommended against reclassification, citing insufficient evidence for safety and efficacy of compounded peptides. However, the committee overseeing the assessment includes peptide boosters, leading many to believe that political pressure — particularly from RFK Jr.'s HHS — will tilt the outcome.
Kennedy's Role
Kennedy's vocal support for peptides has emboldened industry advocates. In an era where health policy is increasingly influenced by celebrity figures and podcast appearances, the FDA faces a credibility test. Critics worry that regulatory decisions could be swayed by popular enthusiasm rather than robust science.
Consumer Risks
Without formal FDA approval for each peptide product, consumers may receive compounds of unknown purity, potency, or sterility. The new Cyclospora outbreak that recently emerged with 72 cases underlines how easily supply chain issues can affect health products. While that outbreak is linked to produce, it highlights the dangers of insufficient regulatory oversight in any health market.
What Changes If the FDA Approves?
If the FDA reclassifies these peptides, the immediate impact will be a surge in telehealth prescriptions and compounding pharmacy production. The agency is expected to issue guidelines on quality control, but enforcement in the compounding sector has historically been inconsistent.
Market Implications
- Telehealth Stocks: Companies like Hims & Hers could see significant revenue growth.
- Compounding Pharmacies: Small and medium pharmacies may gain a new revenue stream, but larger players with more resources could dominate.
- Consumer Access: Patients seeking alternative treatments for pain, recovery, or anti-aging may flood telehealth platforms.
Long-Term Concerns
Medical professionals worry that without rigorous clinical trials, patients may be exposed to ineffective or harmful treatments. The allure of quick fixes for sports injuries or aging could lead to widespread self-medication. Unlike the GLP-1 drugs, which have robust clinical data, many peptides have only anecdotal or preliminary evidence.
The Bigger Picture: Mainstreaming Biohacking
The peptide gold rush represents a broader trend: the mainstreaming of biohacking and wellness culture. Once confined to Reddit forums and gym locker rooms, injectable peptides are now being marketed by major telehealth companies and championed by the nation's top health official.
A New Regulatory Frontier
The FDA's decision could set a precedent for other alternative therapies. If peptides are effectively deregulated through compounding, other substances currently restricted may face similar pressure. This mirrors debates around psychedelics, cannabis, and other treatments that occupy a gray area between medicine and wellness.
Public Health at a Crossroads
While supporters argue for patient autonomy and innovation, skeptics warn of a repeat of the opioid crisis — where aggressive marketing of unproven treatments led to widespread harm. The telehealth industry's ability to reach millions of patients quickly amplifies both the potential benefits and risks.
Parallels with Other News
This story is unfolding against a backdrop of heightened interest in non-traditional health approaches. Meanwhile, in sports, the Glasgow 2026 Commonwealth Games kick off tonight with an opening ceremony, drawing global attention to athletic performance and recovery — a domain where peptides have long been controversial. And in entertainment, Ted Lasso Season 4 returns amid creative turmoil and high stakes, a reminder that even beloved institutions face challenges when scaling up.
Conclusion
The FDA's two-day hearing on peptide reclassification could mark a turning point in how Americans access unapproved treatments. With billions of dollars at stake and an administration that appears sympathetic to deregulation, the outcome may reshape both the telehealth industry and public health policy for years to come.
As the committee deliberates, telehealth companies are ready to flip the switch. Whether that leads to a revolution in personal health or a new wave of harm depends on what guardrails — if any — the FDA puts in place.
"There's an understanding in the industry that something big is happening," said Olympia Pharmaceuticals' Fritzler. For consumers, the big question is whether that something will be safe.
Comments